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7LETTER TO THE EDITOR
atal Early-Onset Epstein-Barr Virus–Associated
osttransplantation Lymphoproliferative Disease
fter Successful Adult Dual-Unit Umbilical Cord Blood
ransplantation
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eEpstein-Barr virus (EBV)–associated posttrans-
lantation lymphoproliferative disease (PTLD) has
een reported in patients after umbilical cord blood
ransplantation (UCBT), with a cumulative incidence
f 2% at 2 years [1]. We report here an unusual case
f a 28-year-old Chinese woman with severe aplastic
nemia for 5 years who developed PTLD after dual-
nit UCBT. Her transplant was from 2 unrelated
onors with 1 mismatched HLA locus (5/6), and she
as conditioned with cyclophosphamide (200 mg/kg
ivided into 4 days), total body irradiation (800 cGy
ivided into 2 days), antithymocyte globulin, and
ethylprednisolone without antiviral prophylaxis. Cy-
losporine and a short course of methotrexate were
sed as prophylaxis of acute graft-versus-host disease
GVHD). The total doses of nucleated cells and
D34 cells were 5.72  107/kg and 2.39  105/kg,
espectively. Initially, DNA short tandem repeat anal-
sis showed engraftment of both donors with a pre-
ominance of donor A on day 21 after transplantation.
onor B cells became predominant on day 28, and by
ay 42, they were the only donor cells to establish
himerism (85% of marrow cells). Engraftment (de-
ned as an absolute neutrophil count 500/L and a
latelet count 20 000/L) with 100% cells from
onor B was delayed until day 77, with no evidence of
cute GVHD. The patient complained of nasal ob-
truction beginning on day 115, and a 4-cm mass was
ound on nasopharyngeal computed tomography. The
iopsy on day 126 showed diffuse inﬁltration of large
mmature cells (expressing CD20, CD79a, and EBV
atent membrane protein 1), which were compatible
ith diffuse large B-cell lymphoma and EBV-associ-
ted PTLD. Meanwhile, uncontrolled gastrointestinal
leeding arose from the disseminated intestinal lym-
homa. Prompt treatment was initiated with reduc-
ion of the immunosuppressant dose and the use of
ituximab, followed by combination chemotherapy
ith cyclophosphamide and prednisolone. Unfortu-
ately, she died of neutropenia with sepsis on day 146,
0 days after the diagnosis of PTLD. t
32Short tandem repeat analysis of the nasopharyn-
eal lymphoma DNA was identical to donor B DNA;
his indicated that the engrafted donor was the source
f the PTLD cells. The patient was EBV seropositive
efore UCBT (viral capsid antigen/immunoglobulin
). However, high-sensitivity nested polymerase chain
eaction with primers speciﬁc to EBV nuclear antigen
could not detect EBV in any blood or marrow cells
f the patient or donors before UCBT. Nevertheless,
fter UCBT, EBV was detected in blood and marrow,
s well as in tissue from the nasopharynx (Figure 1).
The risk of PTLD increased signiﬁcantly with HLA
isparity, ex vivo or in vivo T-cell depletion, and severe
VHD. In early PTLD (6 months after transplanta-
ion), cells are almost EBV positive, and cytotoxic T-cell
mmunity is lowest [2]. Tomonari et al. [3] recently
emonstrated a delay in the recovery of antiviral immu-
ity in UCBT recipients. The recovery of the absolute
ymphocyte count in our case (500/L) on day 77
ccurred 30 days later than that in another chronic
yelogenous leukemia recipient of dual umbilical cord
lood grafts performed at our institution. Although dou-
le chimeras could have been created by UCBT from 2
artially matched unrelated donors and have been shown
o support the reconstitution of hematopoiesis, especially
n the early stage of transplantation [4], several studies
including ours) have shown that only 1 unit could ﬁnally
ngraft [5]. Therefore, as seen in our case, the changing
attern of mixed chimeras after dual-unit UCBT might
elay engraftment and even impair antiviral T-cell im-
unity. Consequently, latently EBV-infected B cells
arbored by the recipient will be reactivated and will
eappear after transplantation, causing transmission of
BV to the newly engrafted donor cells and, ﬁnally,
evelopment of PTLD. After multidonor UCBT, reg-
lar quantitative measurement of EBV DNA may best
e used to enable the prompt rather than the preemptive
reatment of PTLD, as suggested for patients after he-
atopoietic stem cell transplantation [6]. In addition, the
ngraftment kinetics and antiviral immune reconstitu-
ion should be further explored.
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Letter to the Editor
BAlthough UCBT has emerged as a feasible alter-
ative to allogeneic stem cell transplantation, the mul-
iple-donor strategy to overcome the cell-dose limita-
ion substantially increases the risk of EBV-associated
igure 1. EBV detection in sample series. Detection of EBV is
hown in mononuclear cells of peripheral blood, bone marrow, and
ymphoma tissue at the diagnosis of PTLD by using EBV-speciﬁc
olymerase chain reaction. No EBV was detected in the mononu-
lear cells of cord blood from 2 donors or the peripheral blood or
arrow cells from the patient before transplantation. EBV was
dentiﬁed in all samples only after transplantation. The Daudi cell
ine was used as the positive control. CBA, CBB, and NP indicate
ord blood A, cord blood B, and nasopharynx tissue, respectively.
re-PB/BM and Post-PB/BM indicate samples from peripheral
lood and bone marrow before and after UCBT, respectively.TLD, especially in adults. Our case provides evi- T
B&MTence that additional caution is needed before this
rocedure is performed.
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